Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
MDA5 Is a Major Determinant of Developing Symptoms in Critically Ill COVID-19 Patients
in
Antiviral drugs
/ COVID-19
/ COVID-19 vaccines
/ Genome-wide association studies
/ Humoral immunity
/ Immune response (cell-mediated)
/ Innate immunity
/ Interferon
/ M protein
/ Mucosal immunity
/ Phenotypes
/ Replication
/ RNA viruses
/ Severe acute respiratory syndrome coronavirus 2
/ Signal transduction
/ Single-nucleotide polymorphism
2024
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
MDA5 Is a Major Determinant of Developing Symptoms in Critically Ill COVID-19 Patients
by
in
Antiviral drugs
/ COVID-19
/ COVID-19 vaccines
/ Genome-wide association studies
/ Humoral immunity
/ Immune response (cell-mediated)
/ Innate immunity
/ Interferon
/ M protein
/ Mucosal immunity
/ Phenotypes
/ Replication
/ RNA viruses
/ Severe acute respiratory syndrome coronavirus 2
/ Signal transduction
/ Single-nucleotide polymorphism
2024
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
MDA5 Is a Major Determinant of Developing Symptoms in Critically Ill COVID-19 Patients
in
Antiviral drugs
/ COVID-19
/ COVID-19 vaccines
/ Genome-wide association studies
/ Humoral immunity
/ Immune response (cell-mediated)
/ Innate immunity
/ Interferon
/ M protein
/ Mucosal immunity
/ Phenotypes
/ Replication
/ RNA viruses
/ Severe acute respiratory syndrome coronavirus 2
/ Signal transduction
/ Single-nucleotide polymorphism
2024
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
MDA5 Is a Major Determinant of Developing Symptoms in Critically Ill COVID-19 Patients
Journal Article
MDA5 Is a Major Determinant of Developing Symptoms in Critically Ill COVID-19 Patients
2024
Request Book From Autostore
and Choose the Collection Method
Overview
Apart from the skin and mucosal immune barrier, the first line of defense of the human immune system includes MDA5 (ifih1 gene) which acts as a cellular sensor protein for certain viruses including SARS-CoV-2. Upon binding with viral RNA, MDA5 activates cell-intrinsic innate immunity, humoral responses, and MAVS (mitochondrial antiviral signaling). MAVS signaling induces type I and III interferon (IFN) expressions that further induce ISGs (interferon stimulatory genes) expressions to initiate human cell-mediated immune responses and attenuate viral replication. SARS-CoV-2 counteracts by producing NSP1, NSP2, NSP3, NSP5, NSP7, NSP12, ORF3A, ORF9, N, and M protein and directs anti-MDA5 antibody production presumably to antagonize IFN signaling. Furthermore, COVID-19 resembles several diseases that carry anti-MDA5 antibodies and the current COVID-19 vaccines induced anti-MDA5 phenotypes in healthy individuals. GWAS (genome-wide association studies) identified several polymorphisms (SNPs) in the ifih1-ifn pathway genes including rs1990760 in ifih1 that are strongly associated with COVID-19, and the associated risk allele is correlated with reduced IFN production. The genetic association of SNPs in ifih1 and ifih1-ifn pathway genes reinforces the molecular findings of the critical roles of MDA5 in sensing SARS-CoV-2 and subsequently the IFN responses to inhibit viral replication and host immune evasion. Thus, MDA5 or its pathway genes could be targeted for therapeutic development of COVID-19.
Publisher
Springer Nature B.V
This website uses cookies to ensure you get the best experience on our website.